# Apellis Pharmaceuticals, Inc. (APLS) — tender_offer/third_party [announced]
Source: sec.gov · situation sit_1ec28c3bb8a9ba7b756e · public 1843407061888321190 · retrieved 2026-08-20T12:38:13.525Z

## Overview
We are a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.

## Key dates
- Announced 2026-05-06

## Timeline
- 2026-05-06 · SC 14D9/A (0001193125-26-209135): SC 14D9/A - Apellis Pharmaceuticals, Inc. — *We are a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.*
  https://www.sec.gov/Archives/edgar/data/1492422/0001193125-26-209135.txt
- 2026-05-12 · SC 14D9/A (0001193125-26-218136): SC 14D9/A - Apellis Pharmaceuticals, Inc. — *We are a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.*
  https://www.sec.gov/Archives/edgar/data/1492422/0001193125-26-218136.txt

## Citations
- 0001193125-26-209135 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526209135
- 0001193125-26-218136 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526218136